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Abstract
 
Induction of tumor-specific immunity requires that dendritic cells (DCs) efficiently capture and
present tumor antigens to result in the expansion and activation of tumor-specific cytotoxic T
cells. The transition from antigen capture to T cell stimulation requires a maturation signal; in
its absence tolerance, rather than immunity may develop. While immune complexes (ICs) are
able to enhance antigen capture, they can be poor at inducing DC maturation, naive T cell ac-
tivation and protective immunity. We now demonstrate that interfering with the inhibitory
signal delivered by Fc
 
 
 
RIIB on DCs converts ICs to potent maturation agents and results in T
cell activation. Applying this approach to immunization with DCs pulsed ex-vivo with ICs, we
have generated antigen-specific CD8
 
 
 
 T cells in vivo and achieved efficient protective immu-
nity in a murine melanoma model. These data imply that ICs may normally function to main-
tain tolerance through the binding to inhibitory Fc
 
 
 
Rs on DCs, but they can be converted to
potent immunogenic stimuli by selective engagement of activating Fc
 
 
 
Rs. This mechanism
suggests a novel approach to the development of tumor vaccines.
Key words: immune complexes • Fc
 
 
 
 receptors • DC maturation • inhibitory/activating 
receptor pairs • T cell immunity
 
Introduction
 
Elucidation of the mechanisms responsible for protective
immunity against tumors is a prerequisite to the develop-
ment of tumor-specific vaccines and effective immunother-
apy for cancer. Because of their ability to be specifically
captured by dendritic cells (DCs), enhance antigen presen-
tation, and elicit tumor-specific killer T cells, immune
complexes (ICs) are emerging as an attractive means of de-
livering tumor-specific antigens to stimulate protective
immunity (1, 2). DCs have been shown to be a key cell in
the pathway of antigen capture and presentation to T cells,
having the unique ability to directly prime naive CD4
 
 
 
 and
CD8
 
 
 
 T cells (3–5), through their ability to efficiently up-
take, process, and present antigen on MHC class I and II
molecules, together with costimulatory molecules such as
B7 and CD40 (3, 6–8). Furthermore, DCs have been
shown to efficiently present exogenously derived antigens
(e.g., ICs) on MHC class I molecules to naive CD8
 
 
 
 T
cells (9–12), accounting for the phenomenon of cross-
priming (13). However, for DCs to efficiently stimulate T
cells, a process known as maturation is required. Immature
DCs, specialized for antigen capture, undergo maturation
in response to inflammatory cytokines and bacterial prod-
ucts, leading to the upregulation of costimulatory mole-
cules such as B7 and CD40 (3, 5, 7, 14). This requirement
for maturation insures that activation of the immune re-
sponse be coupled to a mechanism capable of discriminating
between endogenous antigens and those derived from ex-
ogenous sources, typically microbial pathogens. Thus, in
the absence of receiving a maturation signal, the interaction
of antigen-presenting immature DCs with T cells can result
in peripheral tolerance (14, 15). The challenge of tumor
vaccination is to find means of overcoming this protective
mechanism and eliciting effective T cell stimulation to en-
dogenous antigens expressed by tumor cells (16–19).
ICs are capable of either enhancing or suppressing the
immune response, resulting from their ability to interact
with Fc
 
 
 
 receptors on B cells, macrophages, or DCs, thus
triggering different cellular responses (20, 21). Engagement
of Fc
 
 
 
 receptors by ICs can lead to either activation or in-
hibitory signaling depending on the specific Fc
 
 
 
R being
 
engaged. Activating Fc
 
 
 
 receptors I and III associate
with the immunoreceptor tyrosine–based activation motif
(ITAM)-containing 
 
 
 
-chain and their engagement by ICs
results in src and syk kinase–mediated activation responses.
In contrast, the inhibitory Fc
 
 
 
 receptor IIB is a single sub-
unit receptor containing a cytoplasmic immunoreceptor ty-
rosine–based inhibition motif (ITIM) domain that inhibits
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ITAM-mediated activation signals through the recruitment
of the inositol-phosphatase SHIP (22, 23). While expres-
sion of the activating/inhibitory receptor pair Fc
 
 
 
RIII/Fc-
 
 
 
RIIB has been described on DCs in mice and humans
(10), the role of these signaling pathways in the biology of
DCs is unclear. Specifically, the ability of ICs to induce
maturation of immature DC through Fc
 
 
 
R activation has
been variable. Dhodapkar et al. failed to observe IC-medi-
ated maturation in human DCs (2), while Regnault et al.
and recently Schuurhuis et al., reported maturation of
mouse DCs in response ICs (10, 12). Since the relative ex-
pression of activating/inhibitory receptors were not defined
in those studies it is possible that IC triggered maturation
may depend on the balance between those opposing
Fc
 
 
 
Rs. More importantly, however, the in vivo implica-
tions of differential ligation of Fc
 
 
 
Rs on DC differentiation
and T cell priming have not been defined.
Therefore, we set out to test the hypothesis that the bal-
ance between activation and inhibitory Fc
 
 
 
Rs on DCs was
critical to induce maturation and effective tumor immu-
nity in vivo in response to ICs. Here we show that DC
predominantly express Fc
 
 
 
RIIB on the surface, and that
interfering with the inhibitory signal delivered by this re-
ceptor enhances the ability of ICs to induce DC matura-
tion. By immunizing with Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 DCs pulsed ex
vivo with ICs we have efficiently generated antigen-spe-
cific CD8
 
 
 
 T cells in vivo and achieved efficient protec-
tive immunity in a murine melanoma model. Our results
indicate that expression of inhibitory Fc
 
 
 
Rs on DCs may
be required to maintain tolerance through binding to IgG–
ICs. However, selective engagement of activating Fc
 
 
 
Rs
by ICs on DCs works as a strong immunogenic signal pro-
moting DC maturation and T cell priming that could elicit
effective antitumor immunity.
 
Materials and Methods
 
Analysis of Fc
 
 
 
R Expression on DCs and T Cell Priming As-
says.
 
Bone marrow–derived DCs were prepared as described
previously (24). DCs were grown from bone marrow progenitors
in RPMI 1640 containing 5% FCS supplemented at 3% vol/vol
with supernatant from J558L cells transduced with murine (m)
GM-CSF. Day 6 DC cultures derived from bone marrows of
wild-type (WT), 
 
 
 
 chain
 
 
 
/
 
 
 
, Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 mice (all in the
C57BL/6 background) were double-stained with anti–CD11c-
PE (HL3; BD PharMingen) and 2.4G2-FITC (BD PharMingen),
1 
 
 
 
g per 5 
 
 
 
 10
 
5
 
 DCs, and analyzed by FACS
 
®
 
. For WT DCs,
2.4G2 binds to both Fc
 
 
 
RIIB and Fc
 
 
 
RIII; for 
 
 
 
 chain
 
 
 
/
 
 
 
 DCs,
2.4G2 binds to Fc
 
 
 
RIIB only; and for Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 DCs, 2.4G2
binds to Fc
 
 
 
RIII only. Background 2.4G2 fluorescence was ob-
tained from DCs in which both Fc
 
 
 
RIIB and 
 
 
 
 chain have been
deleted. For the T cell priming experiments, DCs derived from
bone marrows of WT or Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 mice (C57BL/6 back-
ground) were pulsed for 3 h with 50 ug/ml OVA or OVA-IgG
ICs. After washing, antigen-pulsed DCs (5 
 
 
 
 10
 
3
 
–10
 
5
 
 cells per
well) were cocultured with either H-2K
 
b
 
/OVA– or I-A
 
b
 
/OVA–
specific TCR transgenic T cells (2 
 
 
 
 10
 
5
 
 cells per well), purified
from OT-I and OT-II mice, respectively (25, 26). At 48-h cocul-
ture cells were pulsed with 
 
3
 
[H]-thymidine (1 
 
 
 
Ci 
 
3
 
[H]-thymi-
 
dine per well) and harvested 8 h later for determination of 
 
3
 
[H]-
thymidine incorporation.
 
DC Maturation Assays.
 
Day 6 DC cultures derived from
bone marrows of WT C57BL/6 and Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 mice were in-
cubated for 36 h with 20 
 
 
 
g/ml of ICs made of OVA and anti-
OVA rabbit IgG (0.5 mg anti-OVA rIgG, ICN, per 1 mg OVA;
Calbiochem). For Fc
 
 
 
RIIB blocking, WT DCs were incubated
simultaneously with OVA-ICs and Ly17.2 mAb (supernatant
from K9.361 hybridoma) (27). For LPS-induced maturation,
DCs were incubated with 50 ng/ml LPS. After 36-h incubation,
DCs were double-stained with anti–CD11c-PE (HL3; BD
PharMingen) plus either anti–I-A
 
b
 
-FITC (AF6–120.1; BD Phar-
Mingen) or anti–B7.2-FITC (GL1; BD PharMingen), 1 
 
 
 
g mAb
per 5 
 
 
 
 10
 
5
 
 DCs and analyzed by FACS
 
®
 
.
 
DC Immunization and Tumor Challenge Experiments.
 
Day 6
DC cultures derived from bone marrows of either WT or
Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 mice (C57BL/6 background) were incubated for
6 h with 50 
 
 
 
g/ml of ICs made of OVA and anti-OVA rabbit
IgG (0.5 mg anti-OVA rIgG, ICN, per 1 mg OVA; Calbio-
chem). DCs were washed in PBS and injected in the footpads of
naive syngeneic C57BL/6 mice (2.5 
 
 
 
 10
 
5
 
 DCs per mouse). As
a specificity control mice were immunized with untreated DCs.
2 wk after this single immunization, mice were challenged sub-
cutaneously with a variant of the melanoma B16 tumor line that
expresses full-length OVA as a neo-antigen (MO4) (references
28–30) (5 
 
 
 
 10
 
5
 
 cells per mouse). As an antigen specificity con-
trol mice were challenged with the parental B16 tumor line
(American Type Culture Collection). Tumor appearance and
growth was monitored three times a week, and a mouse was
considered positive when palpable tumors were detected. For
statistical analysis (Student’s 
 
t
 
 test) the Prism™ 2.0 software
(GraphPad) was used.
 
Detection of OVA-specific CD8
 
 
 
 T Cells with H-2K
 
b
 
/OVA Tet-
ramers.
 
Peripheral blood cells obtained 2 wk after challenging
mice with B16-OVA tumor, were double stained with anti–
CD8
 
 
 
-FITC (53–6.7; BD PharMingen) and H-2K
 
b
 
/OVA-PE
tetramers. Tetramer staining was done at 4
 
 
 
C, for 1 h with 1 
 
 
 
g
of anti-CD8
 
 
 
 and tetramers per 10
 
6
 
 cells. H-2K
 
b
 
/OVA tetramers
carried the immunodominant OVA peptide SIINFEKL and were
designed as described previously (31, 32).
 
Results and Discussion
 
To evaluate whether the balance between activation and
inhibitory Fc
 
 
 
Rs on DCs is critical to induce maturation
and effective tumor immunity in vivo in response to ICs,
DCs were generated from bone marrow–derived from
C57BL/6 WT and Fc
 
 
 
R-deficient mice and characterized
for Fc
 
 
 
R surface expression. The relative contributions of
the low-affinity activating (Fc
 
 
 
RIII) and inhibitory (Fc-
 
 
 
RIIB) receptors on the surface of immature DCs was de-
termined by FACS
 
®
 
 analysis of DC isolated from WT and
Fc
 
 
 
R-deficient animals. Fc
 
 
 
RIIB plus RIII expression was
determined by 2.4G2 staining, a mAb that binds equiva-
lently to both receptors (33, 34). The Fc
 
 
 
RIIB component
was determined by 2.4G2 staining on DCs obtained from
mice deficient in the common 
 
 
 
 chain (RI/RIII
 
 
 
/
 
 
 
; refer-
ence 35) which only express Fc
 
 
 
RIIB. The Fc
 
 
 
RIII com-
ponent was determined by staining DCs obtained from Fc-
 
 
 
RIIB-deficient mice with 2.4G2, which on these cells
would only bind to Fc
 
 
 
RIII. As seen in Fig. 1 A, DCs pre- 
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dominantly express inhibitory Fc
 
 
 
RIIB, which accounts
for 
 
 
 
75% of total Fc
 
 R expression. Consistently, the mean
fluorescence intensity on WT DCs observed with the
RIIB-specific Ly17.2 mAb (27) also accounted for  75%
of 2.4G2 staining (data not shown). A similar pattern of
Fc R expression was observed in DCs purified from spleen
(data not shown). These results indicate that resting DCs
express mainly inhibitory Fc RIIB on their surface.
Both WT and Fc RIIB /  immature DCs are equally
able to mediate IC presentation to T cells, as shown in Fig.
1 B. DCs isolated from either WT or Fc RIIB-deficient
mice were incubated with ICs composed of rabbit IgG
anti-OVA and OVA, and then tested for their ability to
mediate antigen presentation to MHC class I– and class II–
restricted OVA-specific T cells (OT-1 and OT-II, respec-
tively) (25, 26). IC-mediated enhancement of MHC class I
and II presentation was equally efficient for both WT and
Fc RIIB /  DCs, indicating that there are no differences
between these cells in their ability to capture and present
IC-derived antigens to class I– or class II–restricted T cells
(Fig. 1 B).
In contrast, DC maturation by ICs was enhanced when
activating Fc Rs were selectively ligated through the use
of Fc RIIB-deficient mice (Fig. 2). In comparison to LPS-
induced maturation, WT DCs are inefficiently induced to
mature in response to ICs, consistent with previous reports
(2, 10, 12). However, a subset of DCs derived from Fc-
 RIIB-deficient mice display a maturation phenotype
comparable to that seen for LPS, with upregulation of
MHC class II (Fig. 2 A) and B7.2 (Fig. 2 B) surface expres-
sion. As seen from the FACS® analysis, this subset of DCs
incubated with ICs show a marked increase in MHC class
II and B7.2 expression, indicative of maturation of these
cells. This effect was not the result of perturbation of DC
development by Fc RIIB deletion, as demonstrated by the
ability of WT DCs to enhance their maturation in response
to ICs when Fc RIIB is blocked by the Fc RIIB-specific
mAb Ly17.2 (Fig. 2 A and B). Furthermore, Fc RIIB-
deficient DCs show equivalent maturation in response to
LPS as compared with WT DCs (Fig. 2 A and B). Con-
versely, and consistent with previous reports (10), IC en-
gagement of DCs derived from   chain–deficient mice
lacking activation Fc Rs does not result in DC maturation
(data not shown). These results indicate that the ability of
ICs to induce DC maturation is determined by the balance
of activation and inhibitory Fc Rs. Selective engagement
of the ITAM-containing Fc Rs by ICs in the absence of
coligation of ITIM-containing inhibitory Fc RIIB results
in enhanced maturation.
The functional consequence of IC-induced maturation
of DCs in vitro was tested in vivo in a murine melanoma
model to determine if DCs induced to mature by selec-
tively engaging activating Fc Rs resulted in enhanced an-
titumor immunity. Fc RIIB /  DCs were pulsed with
OVA–IgG ICs as before and then used to immunize
C57BL/6 mice. As a control, C57BL/6 mice were immu-
nized with WT DCs treated under the same conditions. 2
wk after a single DC immunization, mice were challenged
Figure 1. Fc RIIB is the predominant Fc R on the surface of dendritic
cells and is not required for IC-mediated enhancement of antigen presenta-
tion. (A) Bone marrow–derived DCs were prepared as described previ-
ously (reference 24). Day 6 DC cultures derived from bone marrows of
WT,   chain / , and Fc RIIB /  mice (all in the C57BL/6 background)
were double-stained with anti–CD11c-PE (HL3; BD PharMingen) and
2.4G2-FITC (BD PharMingen), and analyzed by FACS®. For WT DCs,
2.4G2 binds to both Fc RIIB and Fc RIII; for   chain /  DCs, 2.4G2
binds to Fc RIIB only; and for Fc RIIB /  DCs, 2.4G2 binds to Fc RIII
only. Background 2.4G2 fluorescence (dotted lines) was obtained from
DCs in which both Fc RIIB and   chain have been deleted (Fc R null).
One representative histogram for 2.4G2 staining is shown, gating on the
CD11c  DC population. The bar graph shows 2.4G2 mean fluorescence
intensity values (CD11c  gate) from four independent experiments (*P  
0.025); B). For the T cell priming experiments, DCs derived from bone
marrows of WT or Fc RIIB /  mice (C57BL/6 background) were pulsed
for 3 h with 50 ug/ml OVA or OVA-IgG ICs. After washing, antigen-
pulsed DCs (5   103–105 cells per well) were cocultured with either
H-2Kb/OVA– or I-Ab/OVA–specific TCR transgenic T cells, (2   105
cells per well), purified from OT-I and OT-II mice, respectively (25, 26).
At 48-h coculture cells were pulsed with 3[H]-thymidine and harvested 8 h
later for determination of 3[H]-thymidine incorporation.1656 Fc RIIB Deletion Enhances DC Maturation by ICs
either with an OVA-expressing clone of the melanoma
line B16 (28, 30) (Fig. 3 A) or with control B16 cells not
expressing OVA. The animals were scored for the kinetics
of tumor appearance as well as the absolute size of the tu-
mor mass. As shown in Fig. 3, mice immunized with Fc-
 RIIB-deficient DCs pulsed with OVA–IC developed
protective immunity to the tumor challenge, with no de-
tectable tumor appearance, while animals immunized with
Figure 2. Removal of inhibitory Fc  receptor signaling from DCs enhances their maturation by ICs. Day 6 DC cultures derived from bone marrows
of WT C57BL/6 and Fc RIIB /  mice were incubated for 36 h with 20  g/ml of ICs made of OVA and anti-OVA rabbit IgG. For Fc RIIB blocking,
WT DCs were incubated simultaneously with OVA-ICs and Ly17.2 mAb (supernatant from K9.361 hybridoma) (reference 27). For LPS-induced matura-
tion, DCs were incubated with 50 ng/ml LPS. After 36-h incubation DCs were double-stained with anti–CD11c-PE (HL3; BD PharMingen) plus either
anti–I-Ab-FITC (AF6–120.1; BD PharMingen, data shown in A) or anti–B7.2-FITC (GL1; BD PharMingen, data shown in B), 1  g mAb per 5   105
DCs, and analyzed by FACS®. Histograms show representative I-Ab or B7.2 fluorescence intensities for the CD11c  DC population gate. Bar graphs
show the increase of mean fluorescence intensity for I-Ab and B7.2 (CD11c  gate) from four independent experiments.
Figure 3. Removal of inhibitory Fc  receptor sig-
naling on DCs enhances their ability to protect
against tumors. Day 6 DC cultures derived from bone
marrows of either WT or Fc RIIB /  mice
(C57BL/6 background) were incubated for 6 h with
50  g/ml of ICs made of OVA and anti-OVA rabbit
IgG. DCs were washed in PBS and injected in the
footpads of naive syngeneic C57BL/6 mice. 2 wk af-
ter this single immunization, mice were challenged
subcutaneously with a variant of the melanoma B16
tumor line that expresses OVA as a neo-antigen (MO4) (ref-
erences 28–30) (5   105 cells per mouse). Tumor growth was
monitored three times a week and data from three indepen-
dent experiments are shown. (A) Scheme for DC immuniza-
tion and tumor challenge. (B) Tumor growth curves for mice
immunized with OVA–IC-pulsed DCs and challenged with
B16-OVA (mice showing palpable tumors). While WT DCs
and Fc RIIb /  DCs are statistically different (P   0.002),
naive and WT DCs are not (P   0.80). (C) Tumor appear-
ance for mice immunized with OVA–ICs and challenged
with B16-OVA. Mice were considered positive when palpa-
ble tumors were detected. While naive and Fc RIIb /  DCs
are statistically different (P   0.0001), naive and WT-DC
are not (P   0.079).1657 Kalergis and Ravetch Brief Definitive Report
WT DCs pulsed with OVA–ICs developed tumors (Fig. 3
B and C), although with a significant delay in appearance
(Fig. 3 B and C). No tumor protection was observed when
the challenging tumor was the parental B16 line (OVA-
negative). Similarly, neither WT nor Fc BIIB /  unpulsed
DCs protected against B16 or B16-OVA. These results in-
dicate that the antitumor response elicited by immuniza-
tion with OVA–IC-pulsed DCs was antigen (OVA)-spe-
cific (Table I).
To determine the mechanism of this protection by DC
immunization, we tested peripheral blood of mice immu-
nized with OVA-IC–pulsed Fc RIIB /  DCs or WT DCs
for the presence of OVA-specific CD8  T cells. Peripheral
blood CD8  T cells from DC-immunized and tumor-chal-
lenged mice were stained for H-2Kb/OVA tetramers (H-
2Kb/SIINFEKL) (31, 32). OVA-specific CD8  T cells
were only expanded in peripheral blood of mice immu-
nized with Fc RIIB /  DCs pulsed with OVA–IgG ICs
(Fig. 4). These results indicate that Fc RIIB /  DCs have
an enhanced ability to prime antigen-specific CD8  T
lymphocytes in vivo, thus contributing to an effective anti-
gen-specific antitumor immune response.
We conclude by suggesting that effective antitumor im-
munization by ICs requires that selective Fc receptor en-
gagement be achieved to induce DC maturation and thus
efficient CD8  T cell priming. This selectivity may be ac-
complished by blocking the inhibitory Fc receptor or by
engineering the Fc region of the IgG molecule of the IC
to preferentially engage activation and not inhibitory
Fc R (36). Conversely, the preferential expression of the
Table I. Tumor Appearance at 3 wk
Treatment Challenging tumor
Tumor  mice/ 
challenged mice 
Naive B16-OVA 8/8
WT unpulsed B16-OVA 4/4
Fc RIIB /  unpulsed B16-OVA 4/4
WT plus OVA-IC B16-OVA 6/8
Fc RIIB /  plus OVA-IC B16-OVA 1/8
Naive B16 4/4
WT unpulsed B16 4/4
Fc RIIB /  unpulsed B16 4/4
WT plus OVA-IC B16 4/4
Fc RIIB /  plus OVA-IC B16 4/4
DC cultures derived from bone marrows of WT or Fc RIIB /  mice (C57BL/6 background) were pulsed with OVA-IgG ICs and used to immunize
naive syngeneic C57BL/6 mice. 2 wk after this single immunization, mice were challenged subcutaneously with a variant of the melanoma B16 tumor
line that expresses OVA as a neo-antigen (MO4). Data shown are fraction of mice with palpable tumors at 3 wk after tumor challenge. As antigen
specificity controls, some mice were injected with untreated DCs and others were challenged with the parental (OVA negative) B16 tumor line.
Figure 4. Fc RIIB /  DCs efficiently induce expansion
of antigen-specific CD8  T cells. Peripheral blood cells
obtained 2 wk after challenging mice with B16-OVA tu-
mor, were double stained with anti–CD8 -FITC (53–6.7;
BD PharMingen) and H-2Kb/OVA-PE tetramers. Tet-
ramer staining was done at 4 C, for 1 h with 1  g of anti-
CD8  and tetramers per 106 cells. H-2Kb/OVA tetramers
carried the immunodominant OVA peptide SIINFEKL
and were designed as described previously (references 31
and 32). (Left) Naive C57BL/6 mice; (middle) C57BL/6
mice immunized with WT DCs pulsed with OVA-IgG
ICs; (right) C57BL/6 mice immunized with Fc RIIB / 
DC pulsed with OVA-IgG ICs. *P   0.02.1658 Fc RIIB Deletion Enhances DC Maturation by ICs
inhibitory Fc R on immature DCs suggests that matura-
tion and activation of immune responses may not nor-
mally occur in response to IC cross-linking of immature
DCs, and may even provide a mechanism to maintain pe-
ripheral tolerance to self-antigens. Chronic inflammatory
states or reduced inhibitory receptor expression, as has
been documented in autoimmune susceptible mouse
strains (37, 38), might contribute to the loss of tolerance
and expansion of autoreactive lymphocytes by inappropri-
ate activation of DC maturation and subsequent T cell
stimulation. Restoring Fc RIIB expression may thus offer
an approach to reestablishing tolerance.
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